Publications by authors named "C Schuhmacher"
Article Synopsis
- Non-university hospitals in Germany provide most inpatient care, making it crucial to analyze the quality of antimicrobial prescribing in these facilities.
- A study conducted in 2021 across 10 hospitals in Baden-Württemberg revealed that 33% of patients received antimicrobial treatment, with most prescriptions being therapeutic.
- Findings showed low adherence to quality indicators, highlighting the need for improved prescribing practices and the implementation of effective antimicrobial stewardship programs.
Article Synopsis
- Drug information (DI) from hospital pharmacies is essential for safe drug therapy, but its quality needs to be better understood and assessed.
- A study analyzed responses to fictitious inquiries over five years from German hospital pharmacies to evaluate how factors like inquiry complexity, organizational structure, and quality measures affected DI quality.
- Results revealed that specialized DI centers performed better overall, particularly with complex inquiries, and recommended implementing "second look" reviews and enhanced training for pharmacists to improve quality further.
Objectives: Guidelines for drug information (DI) provided by hospital pharmacists call for quality assurance procedures; however, no method of evaluation is internationally agreed on. The procedure should be feasible, reproducible and representative for real-life quality. We tested a new approach using a fictitious enquiry under simulated real-life conditions for quality assessment of DI by German hospital pharmacists.
View Article and Find Full Text PDFDisease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.
Eur J Cancer
December 2019
Introduction: Disease-free survival (DFS) is increasingly being used as surrogate end-point for overall survival (OS) in cancer trials. So far, there has been no validation of the surrogacy of DFS for OS for neoadjuvant treatment of gastroesophageal adenocarcinoma.
Methods: The study uses individual patient data (IPD) from eight randomised controlled trials (RCTs) (n = 1126 patients) comparing neoadjuvant therapy followed by surgery with surgery alone for gastroesophageal adenocarcinoma.
Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).
Eur J Cancer
April 2018
Background: Perioperative chemotherapy significantly improves survival in patients with locally advanced oesophagogastric cancer (EGC). However, as approximately 60% of patients will die from their disease, new therapeutic agents such as molecular-targeted drugs are needed.
Patients And Methods: To evaluate the role of panitumumab with perioperative chemotherapy, previously untreated patients with locally advanced EGC received, in an open-label randomised phase II study (NEOPECX), standard epirubicin, cisplatin, capecitabine (ECX) chemotherapy with or without panitumumab.